Summary.-The hypoxic cell-radiosensitizing drug misonidazole (1-(2-nitroimidazol-1-yl)-3-methoxypropan -2 -ol, Ro 07-0582, MIS) was administered at a dose of 150 mg/kg i.v. to 6 dogs bearing spontaneous tumours, and the resulting tumour concentrations were measured by HPLC analysis. In 4 dogs it was possible to obtain serial biopsy specimens up to 5 h.
Barbiturate anaesthesia was necessary for the removal of the serial biopsy specimens, and the effects of sodium pentobarbitone anaesthesia on the pharmacokinetics of MIS were investigated in 2 dogs. After barbiturate anaesthesia peak plasma concentrations were raised and the availability of MIS was increased, although the biological half-life remained unaltered. The metabolism of MIS to the 0-demethylated metabolite, Ro 05-9963, was delayed initially. The concentrations of MIS and Ro 05-9963 in cerebrospinal fluid were also recorded in these dogs; MIS concentrations were found to approach those of the plasma, whereas the metabolite concentrations were considerably lower (0-58% of the plasma concentration).
THE 2-nitroimidazole, misonidazole (1-(2 -nitroimidazol -I -yl) -3 -methoxypropan -2-ol, Ro 07-0582 MIS) has been shown to be an active hypoxic cell radiosensitizer both in vitro (Asquith et al., 1974; Chapman et al., 1974) and in vivo (Denekamp et al., 1974) . It is generally accepted as being one of the most suitable drugs of its kind currently available for clinical use, and several trials are in progress to assess the effectiveness of this agent as an adjuvant to the radiotherapy of tumours in man (Dische et al., 1977; Urtasun et al., 1977; Wiltshire et al., 1978) .
Most of the experimental work to evaluate this and other radiosensitizing drugs has been carried out in vitro or in rodents. There are, however, some differences between the behaviour of MIS in rodents and in man, in particular the much shorter half-life of the drug in the mouse, which may possibly limit the use of rodents as models for studies of radiosensitization.
From a recent study of MIS in the dog (White et al., 1979) it was concluded, in the light of the similar pharmacokinetic behaviour of the drug in the dog and man, that this may be a useful species to use as an intermediate model between rodents and humans. Notably the half-life of the drug in this species (4.7 h mean) more closely resembles that found in man (4-18 h).
To investigate the pharmacokinetics of MIS in tumour-bearing dogs, and to examine the feasibility of a clinical trial using MIS in this species, we have examined the concentrations of MIS in the tumour and plasma of 6 dogs with spon-taneous tumours. In 4 of these (logs it was possible to obtain multiple biopsy specimens up to 5 h after the administration of t,he drug.
Sodium pentobarbitone was used as an anaesthetic agent for the dogs from which biopsy specimens were taken, and we have therefore examined the effects of this drug on the pharmacokinetics of MIS in 2 dogs uised in this study. The cerebrospinal fluid concentrations of MIS and its 0-demethylated metabolite, Ro 05-9963, were also measured in these dogs.
AIATERIALS AND METHODS

Experimniental dogs
The 2 dogs used in this study -were adult et al. (1978a) . The estimation of pharmacokinetic parameters was made using the methods described previously by White et al. (1979 Before radiotherapy was performed MIS was administered i.v. to each dog. The dogs were then anaesthetized using sodium pentobarbitone at a dose of 30 mg/kg. Blood samples were taken from all dogs at 1, 2, 3, 4 and 5 h. At the same times small biopsy specimens (> 10 mg) were taken from the lesions; samples were also removed for histological examination.
In the case of Dog 3 samples were removed from the major mammary mass and from the satellite nodules at each sampling time.
Samples were taken from separate lesions at each time in the case of Dog 4.
Serial samples were taken from adjacent areas of the lesions at each sampling time for Dogs 5 and 6.
RESULTS
Experimtental data
Misonidazole and sirnultaneous barbitirate anaesthesia. Table III with comments on individual variation between biopsy specimens.
(ii) Plasma MIS and metabolite concentrations. The plasma and tumour concentrations of MIS and Ro 05-9963 in In Case 3 the tumour metabolite concentration rose to a maximum at 2 h andI was maintained at a fairly steady level up to 5. The overall mean tumour:plasma concenitration ratio -was high (97 + 19O/), values at 2 and 3 h showing more than complete penetration by the metabolite.
DISCUSS lON
WVe have studied the concentrations of MIS and its metabolite, Ro 05-9963, in 6 spontaneous canine tumours after doses of 150 mg/kg i.v. in order to investigate the relationship between tumour and plasma concentrations and to elucidate the optimum timing for the irradiation of tumours after the administration of MIS.
Because of the necessity for general anaesthesia in the 4 dogs from which serial biopsy specimens were removed, we have also studied the effect of the simnultaneouis administration of sodiuim pentobarbitone on the pharmacokinetics of MIS in 2 dogs. These findings may be compared w%rith the data previously reported by White et al.
(1 979) for the pharmacokineties of MIS in unanaesthetized dogs.
After sodium pentobarbitone an aesthesia, the pattern of MIS elimination from the plasma was not markedly altered. Peak plasma concentrations occurred at about the same time, anid the half-life of MIS remained witlhin the previously reported range (4.9-6 7 h as compared with a range of 3 2-6 9 h). Some differences were noted, however, firstli, the peak plasnma MIS concentrationis wrere raised after anaesthesia bv 11-13% to values of 200 an(I 223 jtg/ml. How%rever, these values were within the racnge previously found (172-224 tig/ml) at the dose of 150 mg/kg i.v. (WNhite et al., 1979) . Secondly, as a result of the raised peak plasma values the total AU(C after anaesthesia was raised by 23 acnd 34% respectively, to 1942 and 2489 tg/ml.h. These values were rather higher than the previously reported range for this dose (1357-1740 ug/ml.h). Thirdly, the metabolismn of MIS to the 0-demethylated metabolite, Ro 05-9963, appeared to be delayed by barbiturate anaesthesia, reducing and delaying peak plasma concentrations. The total availability of the metabolite, however, remained unaltered.
The delayed metabolism of MIS, which may well be due to competition with the barbiturate for conmmon metabolizing enzymes, probably accounts for the early high MIS concentrations observed in the 2 anaesthetized dogs.
The above findings suggest that peak plasma MIS concentrations would be somewhat higher in the dogs anaesthetized for the purpose of biopsy. This was in fact the case, and all anaesthetized dogs showed peak plasma concentrations at the upper limit of, or greater than, the normal range for this dose (184-225 Htg/ml).
Tumour penetration was good in all cases in this study except Case 2 (meningioma), with values ranging between 47 and 95%0 of the plasma concentration. In Cases 3-6 the maximum tumour concentration was achieved at 1 h, high concentrations being maintained during the first 3 h after drug administration.
MIS appears suitable as a radiosensitizing agent for veterinary radiotherapy, rapid and high concentrations being achieved in tumours after i.v. dosage, and the timing of radiotherapy not critical within the first 3 h after dosage. The range of maximum tumour concentrations achieved in this study again excepting Case 2 (131-198 ,ug/ml) Despite the high degree of penetration recorded in the CSF (1 120o) of Case 2 (meningioma) it appears the dog's braini is only moderately well penetrated by MIS at 3 5 h. The mean concentration found in the brain samples was 114 + 9 jug/ml (47 + 3% of the plasma concentration).
Although there was little variation between the concentrations found in the normal brain, considerable differences were noted between the tumour samples. In the well differentiated and vascular area of Biopsy Specimen 3 the concentration was similar to that elsewhere in normal brain (450o), whilst in the poorly differentiated and relatively avascular areas of Biopsy Specimens 1 and 2 the concentrations represented only 17 and 340% of the plasma concentration. It is debatable whether these variations were attributable to the histological and vascular patterns.
The estimation of the concentration of MIS in tumours will be a valuable guide to the correct timing of radiotherapy to achieve the maximum enhancement of the tumour response, and also in evaluating the likely degree of enhancement. It is important to establish what relationship, if any, exists between tumour anid plasma MIS concentrations.
The mouse has been regarded as a poor species in which to investigate such a relationship, since it has generally been held that the short half-life of MIS in the mouse has led to poor tumour concentrations and a lower tumour: plasma ratio than in man. Dische et al. (1977) reported concentrations of less than 40%0 of the plasma concentration in mouse tumours, and similar levels have been recorded elsewhere (McNally et al., 1978) .
Cenerally higher levels were reported in man by ("ray et al. (1976) but considerable variation was recorded between tumours (12-92%o). Subsequent reports showed less variation, but the same high degree of penetration: 37-107 % (Dische et al., 1977) , 50-70% (Wiltshire et al., 1978) and 50-1 00%0 (Workman et al., 1978b) .
XVith the exception of Case 2 (meningioma) the range of penetration values in this stu(y (47-95°0) closely resembles the range previously reported in man. The mean values for the tumour: plasma ratios for these cases were remarkably constant (69, 71, 66, 67 and 63%) with only small degrees of variation, suggesting that tumour concentrations were largely a function of the available plasma concentrations.
The assumption that the higher tumour penetration values seen in man have been the result of the relatively long half-life of MIS in man has recently been challenged by Brown et al. (1979) , who recorded tumour: plasma ratios ranging from 50 to 70%0 in the mouse, and demonstrated that this level of penetration remained unaltered when the half-life of MIS was artificially prolonged from 1P5 to 10 h by bilateral renal ligation of the mice. These workers concluded that the tumour penetration in mice was in fact similar to that in man and that any variation was likely to be the result of individual tumour type.
With the exception of the brain tumour in this study, the range of tumour penetration values indicated a similar tumour: plasma concentration relationship to both mouse and man. WAe conLcur with the conclusion of Brown et al. (1979) that the tumour concentration is dependant more upon the available plasma concentration than on the half-life of MIS in the particular species.
Although the mouse may well be a better species for the study of tumour penetration by MIS than at first thought, it nmay prove a poor model for the investigation of other radiosensitizing drugs which are more hydrophilic than MIS and have shorter half-lives. The intermediate halflife of MIS in the dog indicates that this species will provide a better opportunity for pharmacokinetic studies of such drugs in a physiologically normal model. Furthermore, the incidence of spontaneous tumours in the dog, of varying histological types, some of which closely resenmble the situation in man, will allow the investigation of tumour penetration by such radiosensitizing drugs and provide a valuable guide to the concentrations likely to be achiieved in tumours in man.
